Clostridium novyi-NT

Drug Profile

Clostridium novyi-NT

Alternative Names: BVD-CNV; BVD-CNV/IT; BVD-CNV/IV; Clostridium novyi-NT spores

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator BioMed Valley Discoveries; Johns Hopkins University
  • Developer BioMed Valley Discoveries
  • Class Bacteria
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(EORTC-NCI-AACR-2016)
  • 13 Jun 2014 Discontinued - Phase-I for Solid tumours (Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 25 Oct 2013 Phase-I clinical trials in Solid tumours (second-line therapy or greater, late-stage disease) in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top